common-pharma-interest patient-centric-marketing-in-the-life-science-industry 
pharmaphorum
JULY 8, 2022
The COVID-19 pandemic has catalysed significant changes in the way pharma develops drugs, particularly in the clinical trial space. A recent Science 37 survey noted that nearly three-quarters (73%) of respondents from the pharma industry were planning a hybrid or DCT, up from 49% in 2021.
pharmaphorum
OCTOBER 2, 2020
The five new NIHR National Patient Recruitment Centres (NPRCs) are set to shape the future of commercial clinical trials in the UK by offering new ways to conduct late-phase, large-scale research projects. How they will engage non-hospitalised patients with common chronic conditions.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
pharmaphorum
OCTOBER 2, 2020
The five new NHS Patient Recruitment Centres (NPRCs) are set to shape the future of commercial clinical trials in the UK by offering new ways to conduct late-phase, large-scale research projects. How they will engage non-hospitalised patients with common chronic conditions.
Intouch Solutions
DECEMBER 6, 2021
” It’s time to examine the ways in which our lives — and those of our patients, our caregivers, our HCPs, and all other stakeholders — have changed in the past two years. Download the PDF. INTRODUCTION Welcome to the new world. It’s time to put aside any leftover notions of “getting back to the way things were.”
pharmaphorum
FEBRUARY 16, 2021
COVID-19 has disrupted markets and accelerated digital adoption but what does this mean for the future of marketing? In this feature, Grünenthal’s Florent Eduoard and Kate Hurtig outline their principles for a new pharmaceutical marketing model. . The R&D focus began to shift, and so did the marketing.
Expert insights. Personalized for you.
100 
Let's personalize your content